#  @Alhmd120690 mohammed alhamad mohammed alhamad posts on X about $ibrx, saudi arabia, this is, investment the most. They currently have [---] followers and [--] posts still getting attention that total [------] engagements in the last [--] hours. ### Engagements: [------] [#](/creator/twitter::1976979685604237312/interactions)  - [--] Week [------] +21% ### Mentions: [--] [#](/creator/twitter::1976979685604237312/posts_active)  ### Followers: [---] [#](/creator/twitter::1976979685604237312/followers)  - [--] Week [---] +80% ### CreatorRank: [-------] [#](/creator/twitter::1976979685604237312/influencer_rank)  ### Social Influence **Social category influence** [finance](/list/finance) [countries](/list/countries) [stocks](/list/stocks) [technology brands](/list/technology-brands) [social networks](/list/social-networks) **Social topic influence** [$ibrx](/topic/$ibrx) #12, [saudi arabia](/topic/saudi-arabia), [this is](/topic/this-is), [investment](/topic/investment) #2947, [volume](/topic/volume), [wall street](/topic/wall-street) #199, [strong](/topic/strong), [close](/topic/close), [wall](/topic/wall), [stocks](/topic/stocks) **Top accounts mentioned or mentioned by** [@bullishbruk](/creator/undefined) [@truedat999](/creator/undefined) [@adamfeuerstein](/creator/undefined) [@buddyandcurry](/creator/undefined) [@petitnong](/creator/undefined) [@dotknightwang](/creator/undefined) [@patricksoonshiong](/creator/undefined) [@idenixixh](/creator/undefined) [@davideyoungmd](/creator/undefined) [@drpatrick](/creator/undefined) [@tb12goat6](/creator/undefined) [@saudifdaen](/creator/undefined) [@shortlovers](/creator/undefined) [@lostamerican22](/creator/undefined) [@vrthomaz](/creator/undefined) [@wafflesnspace](/creator/undefined) [@fcathey13527](/creator/undefined) [@kodaboda2](/creator/undefined) [@epboston](/creator/undefined) [@psea17](/creator/undefined) **Top assets mentioned** [ImmunityBio, Inc. Common Stock (IBRX)](/topic/$ibrx) [Novo-Nordisk (NVO)](/topic/$nvo) [NVIDIA Corp. (NVDA)](/topic/$nvda) ### Top Social Posts Top posts by engagements in the last [--] hours "Shorter have zero stock available 🥳😂😂😂😂 now they must buy to cover their lost $IBRX" [X Link](https://x.com/Alhmd120690/status/2018778999191703751) 2026-02-03T20:09Z [--] followers, [---] engagements "I am from Saudi Arabia and Ive heard from friends working at the Saudi Food and Drug Authority that they are prepared to approve this therapy for multiple cancer indications not limited to a single type. Additionally weve heard that investment funds are considering investing in IBRX" [X Link](https://x.com/Alhmd120690/status/2019786384546869618) 2026-02-06T14:52Z [---] followers, [----] engagements "I am from Saudi Arabia and Ive heard from friends working at the Saudi Food and Drug Authority that they are prepared to approve this therapy for multiple cancer indications not limited to a single type. Additionally weve heard that investment funds are considering investing in IBRX $IBRX https://twitter.com/i/web/status/2019821275154182632 https://twitter.com/i/web/status/2019821275154182632" [X Link](https://x.com/Alhmd120690/status/2019821275154182632) 2026-02-06T17:11Z [---] followers, [--] engagements "I am from Saudi Arabia and Ive heard from friends working at the Saudi Food and Drug Authority that they are prepared to approve this therapy for multiple cancer indications not limited to a single type. Additionally weve heard that investment funds are considering investing in IBRX $IBRX https://twitter.com/i/web/status/2019821498114961784 https://twitter.com/i/web/status/2019821498114961784" [X Link](https://x.com/Alhmd120690/status/2019821498114961784) 2026-02-06T17:12Z [---] followers, [---] engagements "$IBRX Game over for shorts. Saudi FDA just validated ANKTIVA. This is not hype this is regulation approval and revenue paths. Your end is inevitable. $IBRX See you on Monday" [X Link](https://x.com/Alhmd120690/status/2020247433067000274) 2026-02-07T21:24Z [---] followers, 10.7K engagements "Theres a part many people still refuse to see. Some large incumbents benefit from delays because truly disruptive therapies dont just compete they bankrupt outdated models. Resistance isnt always about safety; sometimes its about survival. What matters more: Saudi Arabia has demonstrated the ability to move decisively and with one of the worlds largest pharmaceutical trade relationships with the U.S. collaboration and access pathways are far more flexible than most assume. The bigger picture is this: the Middle East and Asia combined represent a cancer market many times larger than the U.S." [X Link](https://x.com/Alhmd120690/status/2020250656452587749) 2026-02-07T21:37Z [---] followers, [--] engagements "Theres a part many people still refuse to see. Some large incumbents benefit from delays because truly disruptive therapies dont just compete they bankrupt outdated models. Resistance isnt always about safety; sometimes its about survival. What matters more: Saudi Arabia has demonstrated the ability to move decisively and with one of the worlds largest pharmaceutical trade relationships with the U.S. collaboration and access pathways are far more flexible than most assume. The bigger picture is this: the Middle East and Asia combined represent a cancer market many times larger than the U.S." [X Link](https://x.com/Alhmd120690/status/2020251008304083310) 2026-02-07T21:39Z [---] followers, [---] engagements "I met Dr. Patrick Soon-Shiong (@DrPatrick) in Saudi Arabia and spoke with him personally. After the conference I invested heavily in $IBRX not as a trade but as conviction. My decision was driven by two core reasons: Saudi Arabias involvement because when Saudi institutions commit they pursue long-term transformational outcomes. And Dr. Soon-Shiong himself humble exceptionally intelligent and clearly one of the true visionaries of our time. His mission is not money but saving lives. Thats why I along with a group of like-minded investors chose ImmunityBio. We dont just see a company we see a" [X Link](https://x.com/Alhmd120690/status/2020258606675796233) 2026-02-07T22:09Z [---] followers, 12.4K engagements "Significant Saudi and Gulf-based investment funds have already initiated strategic accumulation of the companys shares. The regulatory and commercial framework is structured around a pre-agreed financial arrangement under which payments are made in exchange for pharmaceutical supply delivered in scheduled tranches with exclusive ownership and distribution rights across the Middle East and Asia assigned to Saudi Arabia. This framework has already been finalized and Saudi Arabia has formally assumed responsibility for the regional distribution infrastructure. On the capital markets side" [X Link](https://x.com/Alhmd120690/status/2020279635133780008) 2026-02-07T23:32Z [---] followers, [----] engagements "I respect your view though it appears closer to the narrative often promoted by competing interests than to a comprehensive investment analysis. Holding a Dr. title or adopting a clinical persona does not automatically translate into expertise in business models capital markets or long-term value creation. Academic specializationwhatever the fielddoes not inherently equate to investment insight. From my perspective this opportunity should be evaluated based on execution regulatory positioning scalability and sustainability rather than broad timing assumptions or simplified outcome scenarios." [X Link](https://x.com/Alhmd120690/status/2020281372074475818) 2026-02-07T23:39Z [---] followers, [---] engagements "When looking at the U.S. market today it is difficult to find an oncology-focused medical company that combines regulatory approvals active commercialization and real patient treatment at this stage. This is not a purely developmental storyit is already in the market generating strong growth and beginning to secure approvals outside the U.S. which meaningfully reduces risk compared to early-stage peers. For that reason some believe the current valuation around $6$8 may not fully reflect the long-term picture" [X Link](https://x.com/Alhmd120690/status/2020282394373140825) 2026-02-07T23:43Z [---] followers, [---] engagements "Ive owned RKLB for over [--] years bought at under $10 and I still hold it today. For me investing is not about selling stocks its about managing assets intelligently. Whenever I need cash I sell only 1% of my position. I never liquidate a stock all at once thats not smart investing. Ive been holding NVDA since [----] and MSFT since [----] and I still own both. The logic is simple: Cash loses value over time due to inflation High-quality dominant companies grow and preserve real capital Market pressure and downturns are temporary patient capital always recovers This isnt luck or speculation. Its a" [X Link](https://x.com/Alhmd120690/status/2020356948210639202) 2026-02-08T04:40Z [---] followers, [---] engagements "@petitnong_ True but mark this out watch the news this week 🤓🤓🤓" [X Link](https://x.com/Alhmd120690/status/2020357970136076738) 2026-02-08T04:44Z [---] followers, [----] engagements "@DotknightWang Youre more than welcome 🤍 Saudi hospitality is part of who we are. If you come to Saudi Arabia consider your stay taken care of and a small gift is always customary for our guests. Youll be welcomed with respect generosity and open hearts" [X Link](https://x.com/Alhmd120690/status/2020361111195787768) 2026-02-08T04:56Z [---] followers, [--] engagements "Rocket Lab is no longer just a launch company its building the infrastructure layer of space. Neutron is the turning point. A reusable medium-lift iron rocket designed for scale cadence and cost efficiency. My conviction: $102+ by April $250 by end of [----] Why Because Rocket Lab is positioning itself to become: The space taxi The FedEx of space Very soon servers data centers and critical infrastructure will move to orbit. Low latency security redundancy space will be the next data frontier. And when space logistics become essential the default carrier will matter. Remember this: When space" [X Link](https://x.com/Alhmd120690/status/2020362738581623155) 2026-02-08T05:03Z [---] followers, [---] engagements "$NVO Read carefully 🔴 Important clarification on Hims & compounded semaglutide $NVO Hims has officially announced that it is stopping access to compounded semaglutide pills following constructive conversations with industry stakeholders. The realistic interpretation: regulatory and legal pressure tied to intellectual property rights. 💡 The active ingredient semaglutide is protected IP owned by Novo Nordisk a company known for aggressively enforcing its patentsespecially as the GLP-1 market expands and counterfeit/compounded alternatives grow. ⚠ As of now there is no official announcement" [X Link](https://x.com/Alhmd120690/status/2020501149661438383) 2026-02-08T14:13Z [---] followers, [---] engagements "People are dying right now. In GBM and other terminal cancers waiting for Phase III is not caution its accepting mass death as policy. Phase II is effectively completed and the results are clear consistent and clinically meaningful. So the real question is brutal: Do regulators need one million more deaths before they act Late-stage cancer patients do not have time for endless trials. Chemotherapy and radiation have failed humanity destroying bodies shortening lives and still being defended because they are financially convenient for entrenched systems. When standard care offers near-certain" [X Link](https://x.com/Alhmd120690/status/2020531065442492500) 2026-02-08T16:12Z [---] followers, [---] engagements "Pricing today we will hit [----] little pull back then [----] then close at 6.15-6.20 $IBRX" [X Link](https://x.com/Alhmd120690/status/2020719060153942490) 2026-02-09T04:39Z [---] followers, [----] engagements "6.75 [----] [----] If we close this tonight ( 💥 💥 soon) 🚨🚨🚨 $IBRX" [X Link](https://x.com/Alhmd120690/status/2020953541943362016) 2026-02-09T20:10Z [---] followers, [----] engagements "💥 💥 💥 Booming coming $IBRX #ImmunityBio #BiotechInvesting #CancerTreatment #GlobalMarkets" [X Link](https://x.com/Alhmd120690/status/2020957382613008536) 2026-02-09T20:26Z [---] followers, [---] engagements "7.00 then boooooooooom $IBRX #ImmunityBio #BiotechInvesting #CancerTreatment #GlobalMarkets" [X Link](https://x.com/Alhmd120690/status/2020963675696242691) 2026-02-09T20:51Z [---] followers, [----] engagements "AH - it will be something lets watch $IBRX #ImmunityBio #BiotechInvesting #CancerTreatment #GlobalMarkets" [X Link](https://x.com/Alhmd120690/status/2020965167392227496) 2026-02-09T20:56Z [---] followers, [---] engagements "Staying alert. Im your eyes on the ground in Saudi Arabia. Watch the space.🤓🤓🤓🤓 $IBRX #ImmunityBio #BiotechInvesting #CancerTreatment #GlobalMarkets @petitnong_ True but mark this out watch the news this week 🤓🤓🤓 @petitnong_ True but mark this out watch the news this week 🤓🤓🤓" [X Link](https://x.com/Alhmd120690/status/2021088641183805602) 2026-02-10T05:07Z [---] followers, [----] engagements "@bullishbruk @adamfeuerstein Every hit piece is basically free marketing 😄 Shorts write smart money accumulates volume confirms. Fundamentals stay solid noise fades. From Riyadh to Wall Street the playbook is obvious. $IBRX 🚀🚀🚀 @adamfeuerstein" [X Link](https://x.com/Alhmd120690/status/2021226973150798122) 2026-02-10T14:17Z [---] followers, [---] engagements "Pts for today Back to [----] Then we will see [----] tonight $IBRX #ImmunityBio #BiotechInvesting #CancerTreatment #GlobalMarkets" [X Link](https://x.com/Alhmd120690/status/2021231648772149461) 2026-02-10T14:35Z [---] followers, [---] engagements "I am seeing [----] tonight 🤓 even if we are at [----] $IBRX #ImmunityBio #BiotechInvesting #CancerTreatment #GlobalMarkets" [X Link](https://x.com/anyuser/status/2021236064669639055) 2026-02-10T14:53Z [---] followers, [----] engagements "What happened today in $IBRX was purely technical not bad news not a change in fundamentals. Price hit a major resistance zone (7.1x) Smart money distributed into strength Stops were hunted And algos did their job into the close. RSI reached oversold levels Volume confirms distribution not panic Key support held around the mid-6s This looks like cleanup before the next move not the end of the story. The science hasnt changed. Anktivas trajectory is intact. And in biotech silence often comes right before catalysts. $IBRX #ImmunityBio #Anktiva #Biotech #BiotechStocks #CancerResearch" [X Link](https://x.com/anyuser/status/2021330683281428796) 2026-02-10T21:09Z [---] followers, [----] engagements "What we saw today in $IBRX looks like a final aggressive short attempt into the close. Heavy selling pressure. Maximum fear tactics. Stops flushed. Yet the fundamentals didnt change. The science didnt change. And the setup didnt break. When downside pressure is exhausted and volume returns the unwind can be fast. Do your own research. Understand the risk. But dont confuse volatility with weakness. Sometimes the loudest move comes after the quietest close. We should buy 50-100 stock today Share this tweet $IBRX #ImmunityBio #Anktiva #Biotech #BiotechStocks #Immunotherapy #CancerResearch" [X Link](https://x.com/anyuser/status/2021331529624887706) 2026-02-10T21:12Z [---] followers, [----] engagements "Both can be true. Yes biotech index pressure and algos added downside thats obvious. But $IBRX clearly led the move not followed it. The stock hit a known resistance showed rejection then saw stock-specific stop hunts and accelerated selling into the close. If this were only index-driven: You wouldnt see such a sharp intraday rejection at a precise level You wouldnt see disproportionate volume vs peers And you wouldnt see RSI pushed this deep this fast Index pressure amplified it but the move started and was shaped by $IBRX price action. That distinction matters." [X Link](https://x.com/Alhmd120690/status/2021332218442895479) 2026-02-10T21:15Z [---] followers, [---] engagements "Clinical benefit is no longer a theoretical discussion it is being applied. $IBRXs lead asset Anktiva (N-803) is supported by late-stage peer-reviewed clinical data including: 70% complete response rates in BCG-unresponsive NMIBC Durable responses measured in years not months Consistent immune activation through NK cells and CD8+ T cells This efficacy has already justified real-world clinical use not just trial continuation. Importantly Saudi Arabia has already begun integrating advanced immunotherapies into clinical practice aligned with its national oncology strategy and healthcare" [X Link](https://x.com/anyuser/status/2021345780293042628) 2026-02-10T22:09Z [---] followers, [---] engagements "$IBRX Price Targets (Based on current approvals & pipeline outlook): End of February: $7.20 End of March: $11.50 April: $12.30 May: $14.70 Year-end outlook: $70 if strong positive data emerges around the HIV program $33$39 even without major HIV-related breakthroughs These are fundamental realistic valuation targets not hype. However a parabolic move is possible by late March driven by major news flow and short-covering pressure. Shorts beware this setup is no longer theoretical. 🚀 $IBRX https://twitter.com/i/web/status/2020248897348673934 https://twitter.com/i/web/status/2020248897348673934" [X Link](https://x.com/anyuser/status/2020248897348673934) 2026-02-07T21:30Z [---] followers, [----] engagements "🚨🚨🚨🚨✅✅✅✅ Serious investors will understand this. When a cancer therapy gets blocked its often not because it failed its because it threatens legacy revenue models. With Saudi FDA approval $IBRX has already stepped beyond the single-regulator trap. Add to that the reality that Middle East + Asia represent a cancer market far larger than the U.S. and the valuation framework changes entirely. I focus on regulation + scale + capital flows not headlines. If you track biotech before the crowd does youre in the right place. $IBRX #ImmunityBio #BiotechInvesting #CancerTreatment #GlobalMarkets" [X Link](https://x.com/Alhmd120690/status/2020253593022923204) 2026-02-07T21:49Z [---] followers, [----] engagements "The short interest in $IBRX isnt organic it reflects desperate attempts to suppress a disruptive therapy that threatens entrenched interests. Short-term pressure doesnt change fundamentals. I invest based on long-term value not short-term noise. Cash erodes with inflation while dominant high-quality companies preserve and grow real capital. Thats why I never liquidate positions emotionally. If I need liquidity I trim small percentages not the entire stake. Markets correct narratives shift and patient capital always wins. Remember this: In the first two weeks of March theyll be forced to buy" [X Link](https://x.com/Alhmd120690/status/2020360219595784636) 2026-02-08T04:53Z [---] followers, [---] engagements "Riyadh Kingdom of Saudi Arabia Record short volume. Historic short interest. Float squeezed to the bone. They sold everything they could borrow. And still price refused to die. Thats not strength. Thats control. This is what failure looks like when suppression stops working. While they count shares someone else is counting time. Math always wins. ➕ Accumulation ➖ Desperation Forced Repricing The next move doesnt start on Wall Street. It starts in Riyadh. 🚀 #IBRX #ImmunityBio #WallStreet #USMarkets #ShortInterest #SmartMoney #Repricing #UnderTheRadar" [X Link](https://x.com/Alhmd120690/status/2021096170404089894) 2026-02-10T05:37Z [---] followers, [----] engagements "Eyes on the clock Next [---] minutes should tell the story what do you think $IBRX #ImmunityBio #BiotechInvesting #CancerTreatment #Biotech #Stocks #StockMarket #WallStreet #Trading #DayTrading #GlobalMarkets" [X Link](https://x.com/anyuser/status/2021240792333836750) 2026-02-10T15:12Z [---] followers, [----] engagements "My call: $IBRX above $15 before the end of February. This is a conviction not noise. If it doesnt happen Ill run a cash giveaway by draw for followers then Ill close this account. Remember this clearly: The real game isnt on Wall Street. The game is in Riyadh Saudi arbia Some will remember this post. Others will regret ignoring it. If youre tracking this story repost and save it. $IBRX #ImmunityBio #Anktiva #BiotechStocks #Immunotherapy #Oncology #NKCells #SaudiHealthcare #NASDAQ https://twitter.com/i/web/status/2021349522346012974 https://twitter.com/i/web/status/2021349522346012974" [X Link](https://x.com/anyuser/status/2021349522346012974) 2026-02-10T22:24Z [---] followers, 10.5K engagements "China expanding PD-1 combinations at scale. Japan advancing next-gen CAR-T & proton therapy. Russia announcing oncology vaccines. Innovation moves fast. Paperwork moves thoughtfully. 🗂 From Riyadh to Wall Street capital follows momentum not hesitation. 📈 Lets see who approves first and who just keeps refreshing the page. 👀 $IBRX #Biotech #Oncology #Innovation #GlobalMarkets #WallStreet #FDA https://twitter.com/i/web/status/2021437209224655193 https://twitter.com/i/web/status/2021437209224655193" [X Link](https://x.com/anyuser/status/2021437209224655193) 2026-02-11T04:12Z [---] followers, [----] engagements "Remember when i said we will reach 15$ this feb and beginning of march [----] $IBRX" [X Link](https://x.com/anyuser/status/2022336526999552192) 2026-02-13T15:46Z [---] followers, [----] engagements "$IBRX is not trading like a normal stock right now. This is a high-pressure setup in the biotech sector. The last-hour weakness on Friday does not signal structural breakdown. It reflects a well-known pattern in heavily shorted catalyst-driven stocks. 📊 Technically: The stock remains in a clear consolidation range between $5.80 $7.20 with strong psychological and technical support at $6. The volume spike into the close suggests: ✔ Reactive selling not institutional distribution ✔ Continued short pressure ✔ Quiet accumulation ahead of potential catalysts 📉 Market law is simple: The stronger" [X Link](https://x.com/anyuser/status/2022461720485085244) 2026-02-14T00:03Z [---] followers, [----] engagements "$IBRX is not just a biotech stock This is a battle between long-term investors and short sellers. Fridays move was pressure not weakness. The $6 support is still intact and the $5.80 $7.20 range remains. Market law is simple: The more pressure on a fundamentally improving company the closer the breakout. 🔹 Revenue growth 🔹 Global expansion 🔹 Strategic partnerships 🔹 Strong institutional attention 🔹 Elevated short interest Next week could be the turning point. If $7.20 breaks with strong volume Shorts will have no place to hide. From Riyadh we see the big picture not the short-term noise." [X Link](https://x.com/anyuser/status/2022478858985828593) 2026-02-14T01:11Z [---] followers, [----] engagements "Guys and girls I have some beautiful information 🤫 But unfortunately I cant say it yet 😂 All I can say is this: 💘 We will have two Valentines Days in the same week remember my words. The move is not on Wall Street 📍 The move starts in Riyadh When the time comes youll realize I knew what was coming and the clues were right in front of you 😏🔥 Shorts enjoy these days because whats coming will make you run in the streets 🚀🤣 The challenge is on. The countdown has begun #IBRX #ImmunityBio #ShortSellers #ShortSqueeze #BiotechInvesting #WallStreet #Riyadh #CancerResearch #Stocks #GlobalMarket" [X Link](https://x.com/anyuser/status/2022904388881125622) 2026-02-15T05:22Z [---] followers, [----] engagements "Many investors today are focused only on whether $IBRX can reach $10 or $20. But that is short-term thinking. Real investing starts when you understand what you own not just the current price. Dr. @PatrickSoonShiong has been very clear: ImmunityBio is not a single-drug company. It is a full immune platform designed to reprogram the immune system to fight cancer and infections long term. A platform means the same technology can expand across multiple cancers and diseases. This is exactly how companies like Moderna created massive long-term value after proving their platform. Today ImmunityBio" [X Link](https://x.com/anyuser/status/2023235115233562822) 2026-02-16T03:16Z [---] followers, [----] engagements "Many investors today are focused only on whether $IBRX can reach $10 or $20. But that is short-term thinking. Real investing starts when you understand what you own not just the current price. Dr. @PatrickSoonShiong has been very clear: ImmunityBio is not a single-drug company. It is a full immune platform designed to reprogram the immune system to fight cancer and infections long term. A platform means the same technology can expand across multiple cancers and diseases. This is exactly how companies like Moderna created massive long-term value after proving their platform. Today ImmunityBio" [X Link](https://x.com/anyuser/status/2023235115233562822) 2026-02-16T03:16Z [---] followers, [----] engagements "Adam Remember when I said we would have two Valentines Days in the same week Now its happening. While you were laughing and mocking some of us were accumulating quietly. You keep calling it hype but the market is starting to answer. Keep cheering for the shorts. They will need that motivation when covering begins. This isnt about noise Twitter or opinions. Its about capital strategy and timing. Some people watch the game. Some people move the pieces. And when the re-pricing starts dont say no one warned you. The next move was never on Wall Street. It starts in Riyadh 🚀 $IBRX #ImmunityBio" [X Link](https://x.com/anyuser/status/2023091099166728420) 2026-02-15T17:44Z [---] followers, [----] engagements "Guys and girls I have some beautiful information 🤫 But unfortunately I cant say it yet 😂 All I can say is this: 💘 We will have two Valentines Days in the same week remember my words. The move is not on Wall Street 📍 The move starts in Riyadh When the time comes youll realize I knew what was coming and the clues were right in front of you 😏🔥 Shorts enjoy these days because whats coming will make you run in the streets 🚀🤣 The challenge is on. The countdown has begun #IBRX #ImmunityBio #ShortSellers #ShortSqueeze #BiotechInvesting #WallStreet #Riyadh #CancerResearch #Stocks #GlobalMarket" [X Link](https://x.com/anyuser/status/2022904388881125622) 2026-02-15T05:22Z [---] followers, [----] engagements "A major step forward for treatment options in Saudi Arabia #SFDA has approved Anktiva for adult bladder cancer and lung cancer patientsmarking approval for the worlds first IL-15 receptor superagonist. https://sfda.gov.sa/en/news/5521532 https://sfda.gov.sa/en/news/5521532" [X Link](https://x.com/anyuser/status/2012223071466246581) 2026-01-16T17:59Z 47.9K followers, 26.3K engagements "📊 SOCIAL SENTIMENT (Past 4h) Most Mentioned Across Platforms: [--]. $NVDA - Bearish 📉 [--] mentions (Reddit:1 ST:17) [--]. $INOD - Bullish 📈 [--] mentions (ST:16) [--]. $IBRX - Bearish 📉 [--] mentions (ST:12) Aggregated from multiple platforms #Trading #SocialSentiment http://tradestie.com http://tradestie.com" [X Link](https://x.com/anyuser/status/2022700369902489698) 2026-02-14T15:52Z [---] followers, [---] engagements "@adamfeuerstein @TB12Goat6 @bullishbruk @Saudi_fda_en Get rdy this week Remember before end of this coming week you will see something unexpected 🤣🤣 $IBRX #ImmunityBio #BiotechInvesting #CancerTreatment #GlobalMarkets" [X Link](https://x.com/anyuser/status/2022710571758391680) 2026-02-14T16:32Z [---] followers, [----] engagements "$IBRX is not just a biotech stock This is a battle between long-term investors and short sellers. Fridays move was pressure not weakness. The $6 support is still intact and the $5.80 $7.20 range remains. Market law is simple: The more pressure on a fundamentally improving company the closer the breakout. 🔹 Revenue growth 🔹 Global expansion 🔹 Strategic partnerships 🔹 Strong institutional attention 🔹 Elevated short interest Next week could be the turning point. If $7.20 breaks with strong volume Shorts will have no place to hide. From Riyadh we see the big picture not the short-term noise." [X Link](https://x.com/anyuser/status/2022478858985828593) 2026-02-14T01:11Z [---] followers, [----] engagements "$IBRX is not trading like a normal stock right now. This is a high-pressure setup in the biotech sector. The last-hour weakness on Friday does not signal structural breakdown. It reflects a well-known pattern in heavily shorted catalyst-driven stocks. 📊 Technically: The stock remains in a clear consolidation range between $5.80 $7.20 with strong psychological and technical support at $6. The volume spike into the close suggests: ✔ Reactive selling not institutional distribution ✔ Continued short pressure ✔ Quiet accumulation ahead of potential catalysts 📉 Market law is simple: The stronger" [X Link](https://x.com/anyuser/status/2022461720485085244) 2026-02-14T00:03Z [---] followers, [----] engagements "Remember when i said we will reach 15$ this feb and beginning of march [----] $IBRX" [X Link](https://x.com/anyuser/status/2022336526999552192) 2026-02-13T15:46Z [---] followers, [----] engagements "China expanding PD-1 combinations at scale. Japan advancing next-gen CAR-T & proton therapy. Russia announcing oncology vaccines. Innovation moves fast. Paperwork moves thoughtfully. 🗂 From Riyadh to Wall Street capital follows momentum not hesitation. 📈 Lets see who approves first and who just keeps refreshing the page. 👀 $IBRX #Biotech #Oncology #Innovation #GlobalMarkets #WallStreet #FDA https://twitter.com/i/web/status/2021437209224655193 https://twitter.com/i/web/status/2021437209224655193" [X Link](https://x.com/anyuser/status/2021437209224655193) 2026-02-11T04:12Z [---] followers, [----] engagements "My call: $IBRX above $15 before the end of February. This is a conviction not noise. If it doesnt happen Ill run a cash giveaway by draw for followers then Ill close this account. Remember this clearly: The real game isnt on Wall Street. The game is in Riyadh Saudi arbia Some will remember this post. Others will regret ignoring it. If youre tracking this story repost and save it. $IBRX #ImmunityBio #Anktiva #BiotechStocks #Immunotherapy #Oncology #NKCells #SaudiHealthcare #NASDAQ https://twitter.com/i/web/status/2021349522346012974 https://twitter.com/i/web/status/2021349522346012974" [X Link](https://x.com/anyuser/status/2021349522346012974) 2026-02-10T22:24Z [---] followers, 10.5K engagements "It will be interesting to see how short positions react over the next few days. The market has already been given plenty of signals now price action and volume will do the talking. 🚀" [X Link](https://x.com/anyuser/status/2021431410226254025) 2026-02-11T03:49Z [---] followers, [---] engagements "RT @truedat999: $IBRX GAMMA + SHORT SQUEEZE LOADED Hold $7.50 & Watch Shorts Panic to $11$12🔥 @IdenixixH Spot on Real-time short intere" [X Link](https://x.com/anyuser/status/2021430009488130169) 2026-02-11T03:44Z [---] followers, [--] engagements "$IBRX GAMMA + SHORT SQUEEZE LOADED Hold $7.50 & Watch Shorts Panic to $11$12🔥 @IdenixixH Spot on Real-time short interest 135M (40%+ float) per Fintel/NASDAQ borrow rates high (8.89%) days to cover [---] (shorts need a full week+ to escape if volume stays hot). Official next report: Settlement Jan [--] (out Feb 3) then Feb [--] (out Feb 18) daily data building the pressure Gamma squeeze fuel loading tons of call options bets at $7.5 & $10 mean big firms might have to buy shares to hedge creating extra upward rocket power if we break higher Closed $6.93 yesterday (+14.5%) holding $7 today. Buy &" [X Link](https://x.com/anyuser/status/2021323235493855474) 2026-02-10T20:39Z [----] followers, [----] engagements "$IBRX Short interest now at [---------] shares. This is 40% of the float. This is very exciting news to me" [X Link](https://x.com/anyuser/status/2021302266905391282) 2026-02-10T19:16Z [---] followers, [----] engagements "Clinical benefit is no longer a theoretical discussion it is being applied. $IBRXs lead asset Anktiva (N-803) is supported by late-stage peer-reviewed clinical data including: 70% complete response rates in BCG-unresponsive NMIBC Durable responses measured in years not months Consistent immune activation through NK cells and CD8+ T cells This efficacy has already justified real-world clinical use not just trial continuation. Importantly Saudi Arabia has already begun integrating advanced immunotherapies into clinical practice aligned with its national oncology strategy and healthcare" [X Link](https://x.com/anyuser/status/2021345780293042628) 2026-02-10T22:09Z [---] followers, [---] engagements "What we saw today in $IBRX looks like a final aggressive short attempt into the close. Heavy selling pressure. Maximum fear tactics. Stops flushed. Yet the fundamentals didnt change. The science didnt change. And the setup didnt break. When downside pressure is exhausted and volume returns the unwind can be fast. Do your own research. Understand the risk. But dont confuse volatility with weakness. Sometimes the loudest move comes after the quietest close. We should buy 50-100 stock today Share this tweet $IBRX #ImmunityBio #Anktiva #Biotech #BiotechStocks #Immunotherapy #CancerResearch" [X Link](https://x.com/anyuser/status/2021331529624887706) 2026-02-10T21:12Z [---] followers, [----] engagements "What happened today in $IBRX was purely technical not bad news not a change in fundamentals. Price hit a major resistance zone (7.1x) Smart money distributed into strength Stops were hunted And algos did their job into the close. RSI reached oversold levels Volume confirms distribution not panic Key support held around the mid-6s This looks like cleanup before the next move not the end of the story. The science hasnt changed. Anktivas trajectory is intact. And in biotech silence often comes right before catalysts. $IBRX #ImmunityBio #Anktiva #Biotech #BiotechStocks #CancerResearch" [X Link](https://x.com/anyuser/status/2021330683281428796) 2026-02-10T21:09Z [---] followers, [----] engagements "if you did this about trading" [X Link](https://x.com/anyuser/status/2020607526400561648) 2026-02-08T21:15Z 175.8K followers, 121.1K engagements "Eyes on the clock Next [---] minutes should tell the story what do you think $IBRX #ImmunityBio #BiotechInvesting #CancerTreatment #Biotech #Stocks #StockMarket #WallStreet #Trading #DayTrading #GlobalMarkets" [X Link](https://x.com/anyuser/status/2021240792333836750) 2026-02-10T15:12Z [---] followers, [----] engagements "I am seeing [----] tonight 🤓 even if we are at [----] $IBRX #ImmunityBio #BiotechInvesting #CancerTreatment #GlobalMarkets" [X Link](https://x.com/anyuser/status/2021236064669639055) 2026-02-10T14:53Z [---] followers, [----] engagements Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing
@Alhmd120690 mohammed alhamad
mohammed alhamad posts on X about $ibrx, saudi arabia, this is, investment the most. They currently have [---] followers and [--] posts still getting attention that total [------] engagements in the last [--] hours.
Engagements: [------] #
- [--] Week [------] +21%
Mentions: [--] #
Followers: [---] #
- [--] Week [---] +80%
CreatorRank: [-------] #
Social Influence
Social category influence finance countries stocks technology brands social networks
Social topic influence $ibrx #12, saudi arabia, this is, investment #2947, volume, wall street #199, strong, close, wall, stocks
Top accounts mentioned or mentioned by @bullishbruk @truedat999 @adamfeuerstein @buddyandcurry @petitnong @dotknightwang @patricksoonshiong @idenixixh @davideyoungmd @drpatrick @tb12goat6 @saudifdaen @shortlovers @lostamerican22 @vrthomaz @wafflesnspace @fcathey13527 @kodaboda2 @epboston @psea17
Top assets mentioned ImmunityBio, Inc. Common Stock (IBRX) Novo-Nordisk (NVO) NVIDIA Corp. (NVDA)
Top Social Posts
Top posts by engagements in the last [--] hours
"Shorter have zero stock available 🥳😂😂😂😂 now they must buy to cover their lost $IBRX"
X Link 2026-02-03T20:09Z [--] followers, [---] engagements
"I am from Saudi Arabia and Ive heard from friends working at the Saudi Food and Drug Authority that they are prepared to approve this therapy for multiple cancer indications not limited to a single type. Additionally weve heard that investment funds are considering investing in IBRX"
X Link 2026-02-06T14:52Z [---] followers, [----] engagements
"I am from Saudi Arabia and Ive heard from friends working at the Saudi Food and Drug Authority that they are prepared to approve this therapy for multiple cancer indications not limited to a single type. Additionally weve heard that investment funds are considering investing in IBRX $IBRX https://twitter.com/i/web/status/2019821275154182632 https://twitter.com/i/web/status/2019821275154182632"
X Link 2026-02-06T17:11Z [---] followers, [--] engagements
"I am from Saudi Arabia and Ive heard from friends working at the Saudi Food and Drug Authority that they are prepared to approve this therapy for multiple cancer indications not limited to a single type. Additionally weve heard that investment funds are considering investing in IBRX $IBRX https://twitter.com/i/web/status/2019821498114961784 https://twitter.com/i/web/status/2019821498114961784"
X Link 2026-02-06T17:12Z [---] followers, [---] engagements
"$IBRX Game over for shorts. Saudi FDA just validated ANKTIVA. This is not hype this is regulation approval and revenue paths. Your end is inevitable. $IBRX See you on Monday"
X Link 2026-02-07T21:24Z [---] followers, 10.7K engagements
"Theres a part many people still refuse to see. Some large incumbents benefit from delays because truly disruptive therapies dont just compete they bankrupt outdated models. Resistance isnt always about safety; sometimes its about survival. What matters more: Saudi Arabia has demonstrated the ability to move decisively and with one of the worlds largest pharmaceutical trade relationships with the U.S. collaboration and access pathways are far more flexible than most assume. The bigger picture is this: the Middle East and Asia combined represent a cancer market many times larger than the U.S."
X Link 2026-02-07T21:37Z [---] followers, [--] engagements
"Theres a part many people still refuse to see. Some large incumbents benefit from delays because truly disruptive therapies dont just compete they bankrupt outdated models. Resistance isnt always about safety; sometimes its about survival. What matters more: Saudi Arabia has demonstrated the ability to move decisively and with one of the worlds largest pharmaceutical trade relationships with the U.S. collaboration and access pathways are far more flexible than most assume. The bigger picture is this: the Middle East and Asia combined represent a cancer market many times larger than the U.S."
X Link 2026-02-07T21:39Z [---] followers, [---] engagements
"I met Dr. Patrick Soon-Shiong (@DrPatrick) in Saudi Arabia and spoke with him personally. After the conference I invested heavily in $IBRX not as a trade but as conviction. My decision was driven by two core reasons: Saudi Arabias involvement because when Saudi institutions commit they pursue long-term transformational outcomes. And Dr. Soon-Shiong himself humble exceptionally intelligent and clearly one of the true visionaries of our time. His mission is not money but saving lives. Thats why I along with a group of like-minded investors chose ImmunityBio. We dont just see a company we see a"
X Link 2026-02-07T22:09Z [---] followers, 12.4K engagements
"Significant Saudi and Gulf-based investment funds have already initiated strategic accumulation of the companys shares. The regulatory and commercial framework is structured around a pre-agreed financial arrangement under which payments are made in exchange for pharmaceutical supply delivered in scheduled tranches with exclusive ownership and distribution rights across the Middle East and Asia assigned to Saudi Arabia. This framework has already been finalized and Saudi Arabia has formally assumed responsibility for the regional distribution infrastructure. On the capital markets side"
X Link 2026-02-07T23:32Z [---] followers, [----] engagements
"I respect your view though it appears closer to the narrative often promoted by competing interests than to a comprehensive investment analysis. Holding a Dr. title or adopting a clinical persona does not automatically translate into expertise in business models capital markets or long-term value creation. Academic specializationwhatever the fielddoes not inherently equate to investment insight. From my perspective this opportunity should be evaluated based on execution regulatory positioning scalability and sustainability rather than broad timing assumptions or simplified outcome scenarios."
X Link 2026-02-07T23:39Z [---] followers, [---] engagements
"When looking at the U.S. market today it is difficult to find an oncology-focused medical company that combines regulatory approvals active commercialization and real patient treatment at this stage. This is not a purely developmental storyit is already in the market generating strong growth and beginning to secure approvals outside the U.S. which meaningfully reduces risk compared to early-stage peers. For that reason some believe the current valuation around $6$8 may not fully reflect the long-term picture"
X Link 2026-02-07T23:43Z [---] followers, [---] engagements
"Ive owned RKLB for over [--] years bought at under $10 and I still hold it today. For me investing is not about selling stocks its about managing assets intelligently. Whenever I need cash I sell only 1% of my position. I never liquidate a stock all at once thats not smart investing. Ive been holding NVDA since [----] and MSFT since [----] and I still own both. The logic is simple: Cash loses value over time due to inflation High-quality dominant companies grow and preserve real capital Market pressure and downturns are temporary patient capital always recovers This isnt luck or speculation. Its a"
X Link 2026-02-08T04:40Z [---] followers, [---] engagements
"@petitnong_ True but mark this out watch the news this week 🤓🤓🤓"
X Link 2026-02-08T04:44Z [---] followers, [----] engagements
"@DotknightWang Youre more than welcome 🤍 Saudi hospitality is part of who we are. If you come to Saudi Arabia consider your stay taken care of and a small gift is always customary for our guests. Youll be welcomed with respect generosity and open hearts"
X Link 2026-02-08T04:56Z [---] followers, [--] engagements
"Rocket Lab is no longer just a launch company its building the infrastructure layer of space. Neutron is the turning point. A reusable medium-lift iron rocket designed for scale cadence and cost efficiency. My conviction: $102+ by April $250 by end of [----] Why Because Rocket Lab is positioning itself to become: The space taxi The FedEx of space Very soon servers data centers and critical infrastructure will move to orbit. Low latency security redundancy space will be the next data frontier. And when space logistics become essential the default carrier will matter. Remember this: When space"
X Link 2026-02-08T05:03Z [---] followers, [---] engagements
"$NVO Read carefully 🔴 Important clarification on Hims & compounded semaglutide $NVO Hims has officially announced that it is stopping access to compounded semaglutide pills following constructive conversations with industry stakeholders. The realistic interpretation: regulatory and legal pressure tied to intellectual property rights. 💡 The active ingredient semaglutide is protected IP owned by Novo Nordisk a company known for aggressively enforcing its patentsespecially as the GLP-1 market expands and counterfeit/compounded alternatives grow. ⚠ As of now there is no official announcement"
X Link 2026-02-08T14:13Z [---] followers, [---] engagements
"People are dying right now. In GBM and other terminal cancers waiting for Phase III is not caution its accepting mass death as policy. Phase II is effectively completed and the results are clear consistent and clinically meaningful. So the real question is brutal: Do regulators need one million more deaths before they act Late-stage cancer patients do not have time for endless trials. Chemotherapy and radiation have failed humanity destroying bodies shortening lives and still being defended because they are financially convenient for entrenched systems. When standard care offers near-certain"
X Link 2026-02-08T16:12Z [---] followers, [---] engagements
"Pricing today we will hit [----] little pull back then [----] then close at 6.15-6.20 $IBRX"
X Link 2026-02-09T04:39Z [---] followers, [----] engagements
"6.75 [----] [----] If we close this tonight ( 💥 💥 soon) 🚨🚨🚨 $IBRX"
X Link 2026-02-09T20:10Z [---] followers, [----] engagements
"💥 💥 💥 Booming coming $IBRX #ImmunityBio #BiotechInvesting #CancerTreatment #GlobalMarkets"
X Link 2026-02-09T20:26Z [---] followers, [---] engagements
"7.00 then boooooooooom $IBRX #ImmunityBio #BiotechInvesting #CancerTreatment #GlobalMarkets"
X Link 2026-02-09T20:51Z [---] followers, [----] engagements
"AH - it will be something lets watch $IBRX #ImmunityBio #BiotechInvesting #CancerTreatment #GlobalMarkets"
X Link 2026-02-09T20:56Z [---] followers, [---] engagements
"Staying alert. Im your eyes on the ground in Saudi Arabia. Watch the space.🤓🤓🤓🤓 $IBRX #ImmunityBio #BiotechInvesting #CancerTreatment #GlobalMarkets @petitnong_ True but mark this out watch the news this week 🤓🤓🤓 @petitnong_ True but mark this out watch the news this week 🤓🤓🤓"
X Link 2026-02-10T05:07Z [---] followers, [----] engagements
"@bullishbruk @adamfeuerstein Every hit piece is basically free marketing 😄 Shorts write smart money accumulates volume confirms. Fundamentals stay solid noise fades. From Riyadh to Wall Street the playbook is obvious. $IBRX 🚀🚀🚀 @adamfeuerstein"
X Link 2026-02-10T14:17Z [---] followers, [---] engagements
"Pts for today Back to [----] Then we will see [----] tonight $IBRX #ImmunityBio #BiotechInvesting #CancerTreatment #GlobalMarkets"
X Link 2026-02-10T14:35Z [---] followers, [---] engagements
"I am seeing [----] tonight 🤓 even if we are at [----] $IBRX #ImmunityBio #BiotechInvesting #CancerTreatment #GlobalMarkets"
X Link 2026-02-10T14:53Z [---] followers, [----] engagements
"What happened today in $IBRX was purely technical not bad news not a change in fundamentals. Price hit a major resistance zone (7.1x) Smart money distributed into strength Stops were hunted And algos did their job into the close. RSI reached oversold levels Volume confirms distribution not panic Key support held around the mid-6s This looks like cleanup before the next move not the end of the story. The science hasnt changed. Anktivas trajectory is intact. And in biotech silence often comes right before catalysts. $IBRX #ImmunityBio #Anktiva #Biotech #BiotechStocks #CancerResearch"
X Link 2026-02-10T21:09Z [---] followers, [----] engagements
"What we saw today in $IBRX looks like a final aggressive short attempt into the close. Heavy selling pressure. Maximum fear tactics. Stops flushed. Yet the fundamentals didnt change. The science didnt change. And the setup didnt break. When downside pressure is exhausted and volume returns the unwind can be fast. Do your own research. Understand the risk. But dont confuse volatility with weakness. Sometimes the loudest move comes after the quietest close. We should buy 50-100 stock today Share this tweet $IBRX #ImmunityBio #Anktiva #Biotech #BiotechStocks #Immunotherapy #CancerResearch"
X Link 2026-02-10T21:12Z [---] followers, [----] engagements
"Both can be true. Yes biotech index pressure and algos added downside thats obvious. But $IBRX clearly led the move not followed it. The stock hit a known resistance showed rejection then saw stock-specific stop hunts and accelerated selling into the close. If this were only index-driven: You wouldnt see such a sharp intraday rejection at a precise level You wouldnt see disproportionate volume vs peers And you wouldnt see RSI pushed this deep this fast Index pressure amplified it but the move started and was shaped by $IBRX price action. That distinction matters."
X Link 2026-02-10T21:15Z [---] followers, [---] engagements
"Clinical benefit is no longer a theoretical discussion it is being applied. $IBRXs lead asset Anktiva (N-803) is supported by late-stage peer-reviewed clinical data including: 70% complete response rates in BCG-unresponsive NMIBC Durable responses measured in years not months Consistent immune activation through NK cells and CD8+ T cells This efficacy has already justified real-world clinical use not just trial continuation. Importantly Saudi Arabia has already begun integrating advanced immunotherapies into clinical practice aligned with its national oncology strategy and healthcare"
X Link 2026-02-10T22:09Z [---] followers, [---] engagements
"$IBRX Price Targets (Based on current approvals & pipeline outlook): End of February: $7.20 End of March: $11.50 April: $12.30 May: $14.70 Year-end outlook: $70 if strong positive data emerges around the HIV program $33$39 even without major HIV-related breakthroughs These are fundamental realistic valuation targets not hype. However a parabolic move is possible by late March driven by major news flow and short-covering pressure. Shorts beware this setup is no longer theoretical. 🚀 $IBRX https://twitter.com/i/web/status/2020248897348673934 https://twitter.com/i/web/status/2020248897348673934"
X Link 2026-02-07T21:30Z [---] followers, [----] engagements
"🚨🚨🚨🚨✅✅✅✅ Serious investors will understand this. When a cancer therapy gets blocked its often not because it failed its because it threatens legacy revenue models. With Saudi FDA approval $IBRX has already stepped beyond the single-regulator trap. Add to that the reality that Middle East + Asia represent a cancer market far larger than the U.S. and the valuation framework changes entirely. I focus on regulation + scale + capital flows not headlines. If you track biotech before the crowd does youre in the right place. $IBRX #ImmunityBio #BiotechInvesting #CancerTreatment #GlobalMarkets"
X Link 2026-02-07T21:49Z [---] followers, [----] engagements
"The short interest in $IBRX isnt organic it reflects desperate attempts to suppress a disruptive therapy that threatens entrenched interests. Short-term pressure doesnt change fundamentals. I invest based on long-term value not short-term noise. Cash erodes with inflation while dominant high-quality companies preserve and grow real capital. Thats why I never liquidate positions emotionally. If I need liquidity I trim small percentages not the entire stake. Markets correct narratives shift and patient capital always wins. Remember this: In the first two weeks of March theyll be forced to buy"
X Link 2026-02-08T04:53Z [---] followers, [---] engagements
"Riyadh Kingdom of Saudi Arabia Record short volume. Historic short interest. Float squeezed to the bone. They sold everything they could borrow. And still price refused to die. Thats not strength. Thats control. This is what failure looks like when suppression stops working. While they count shares someone else is counting time. Math always wins. ➕ Accumulation ➖ Desperation Forced Repricing The next move doesnt start on Wall Street. It starts in Riyadh. 🚀 #IBRX #ImmunityBio #WallStreet #USMarkets #ShortInterest #SmartMoney #Repricing #UnderTheRadar"
X Link 2026-02-10T05:37Z [---] followers, [----] engagements
"Eyes on the clock Next [---] minutes should tell the story what do you think $IBRX #ImmunityBio #BiotechInvesting #CancerTreatment #Biotech #Stocks #StockMarket #WallStreet #Trading #DayTrading #GlobalMarkets"
X Link 2026-02-10T15:12Z [---] followers, [----] engagements
"My call: $IBRX above $15 before the end of February. This is a conviction not noise. If it doesnt happen Ill run a cash giveaway by draw for followers then Ill close this account. Remember this clearly: The real game isnt on Wall Street. The game is in Riyadh Saudi arbia Some will remember this post. Others will regret ignoring it. If youre tracking this story repost and save it. $IBRX #ImmunityBio #Anktiva #BiotechStocks #Immunotherapy #Oncology #NKCells #SaudiHealthcare #NASDAQ https://twitter.com/i/web/status/2021349522346012974 https://twitter.com/i/web/status/2021349522346012974"
X Link 2026-02-10T22:24Z [---] followers, 10.5K engagements
"China expanding PD-1 combinations at scale. Japan advancing next-gen CAR-T & proton therapy. Russia announcing oncology vaccines. Innovation moves fast. Paperwork moves thoughtfully. 🗂 From Riyadh to Wall Street capital follows momentum not hesitation. 📈 Lets see who approves first and who just keeps refreshing the page. 👀 $IBRX #Biotech #Oncology #Innovation #GlobalMarkets #WallStreet #FDA https://twitter.com/i/web/status/2021437209224655193 https://twitter.com/i/web/status/2021437209224655193"
X Link 2026-02-11T04:12Z [---] followers, [----] engagements
"Remember when i said we will reach 15$ this feb and beginning of march [----] $IBRX"
X Link 2026-02-13T15:46Z [---] followers, [----] engagements
"$IBRX is not trading like a normal stock right now. This is a high-pressure setup in the biotech sector. The last-hour weakness on Friday does not signal structural breakdown. It reflects a well-known pattern in heavily shorted catalyst-driven stocks. 📊 Technically: The stock remains in a clear consolidation range between $5.80 $7.20 with strong psychological and technical support at $6. The volume spike into the close suggests: ✔ Reactive selling not institutional distribution ✔ Continued short pressure ✔ Quiet accumulation ahead of potential catalysts 📉 Market law is simple: The stronger"
X Link 2026-02-14T00:03Z [---] followers, [----] engagements
"$IBRX is not just a biotech stock This is a battle between long-term investors and short sellers. Fridays move was pressure not weakness. The $6 support is still intact and the $5.80 $7.20 range remains. Market law is simple: The more pressure on a fundamentally improving company the closer the breakout. 🔹 Revenue growth 🔹 Global expansion 🔹 Strategic partnerships 🔹 Strong institutional attention 🔹 Elevated short interest Next week could be the turning point. If $7.20 breaks with strong volume Shorts will have no place to hide. From Riyadh we see the big picture not the short-term noise."
X Link 2026-02-14T01:11Z [---] followers, [----] engagements
"Guys and girls I have some beautiful information 🤫 But unfortunately I cant say it yet 😂 All I can say is this: 💘 We will have two Valentines Days in the same week remember my words. The move is not on Wall Street 📍 The move starts in Riyadh When the time comes youll realize I knew what was coming and the clues were right in front of you 😏🔥 Shorts enjoy these days because whats coming will make you run in the streets 🚀🤣 The challenge is on. The countdown has begun #IBRX #ImmunityBio #ShortSellers #ShortSqueeze #BiotechInvesting #WallStreet #Riyadh #CancerResearch #Stocks #GlobalMarket"
X Link 2026-02-15T05:22Z [---] followers, [----] engagements
"Many investors today are focused only on whether $IBRX can reach $10 or $20. But that is short-term thinking. Real investing starts when you understand what you own not just the current price. Dr. @PatrickSoonShiong has been very clear: ImmunityBio is not a single-drug company. It is a full immune platform designed to reprogram the immune system to fight cancer and infections long term. A platform means the same technology can expand across multiple cancers and diseases. This is exactly how companies like Moderna created massive long-term value after proving their platform. Today ImmunityBio"
X Link 2026-02-16T03:16Z [---] followers, [----] engagements
"Many investors today are focused only on whether $IBRX can reach $10 or $20. But that is short-term thinking. Real investing starts when you understand what you own not just the current price. Dr. @PatrickSoonShiong has been very clear: ImmunityBio is not a single-drug company. It is a full immune platform designed to reprogram the immune system to fight cancer and infections long term. A platform means the same technology can expand across multiple cancers and diseases. This is exactly how companies like Moderna created massive long-term value after proving their platform. Today ImmunityBio"
X Link 2026-02-16T03:16Z [---] followers, [----] engagements
"Adam Remember when I said we would have two Valentines Days in the same week Now its happening. While you were laughing and mocking some of us were accumulating quietly. You keep calling it hype but the market is starting to answer. Keep cheering for the shorts. They will need that motivation when covering begins. This isnt about noise Twitter or opinions. Its about capital strategy and timing. Some people watch the game. Some people move the pieces. And when the re-pricing starts dont say no one warned you. The next move was never on Wall Street. It starts in Riyadh 🚀 $IBRX #ImmunityBio"
X Link 2026-02-15T17:44Z [---] followers, [----] engagements
"Guys and girls I have some beautiful information 🤫 But unfortunately I cant say it yet 😂 All I can say is this: 💘 We will have two Valentines Days in the same week remember my words. The move is not on Wall Street 📍 The move starts in Riyadh When the time comes youll realize I knew what was coming and the clues were right in front of you 😏🔥 Shorts enjoy these days because whats coming will make you run in the streets 🚀🤣 The challenge is on. The countdown has begun #IBRX #ImmunityBio #ShortSellers #ShortSqueeze #BiotechInvesting #WallStreet #Riyadh #CancerResearch #Stocks #GlobalMarket"
X Link 2026-02-15T05:22Z [---] followers, [----] engagements
"A major step forward for treatment options in Saudi Arabia #SFDA has approved Anktiva for adult bladder cancer and lung cancer patientsmarking approval for the worlds first IL-15 receptor superagonist. https://sfda.gov.sa/en/news/5521532 https://sfda.gov.sa/en/news/5521532"
X Link 2026-01-16T17:59Z 47.9K followers, 26.3K engagements
"📊 SOCIAL SENTIMENT (Past 4h) Most Mentioned Across Platforms: [--]. $NVDA - Bearish 📉 [--] mentions (Reddit:1 ST:17) [--]. $INOD - Bullish 📈 [--] mentions (ST:16) [--]. $IBRX - Bearish 📉 [--] mentions (ST:12) Aggregated from multiple platforms #Trading #SocialSentiment http://tradestie.com http://tradestie.com"
X Link 2026-02-14T15:52Z [---] followers, [---] engagements
"@adamfeuerstein @TB12Goat6 @bullishbruk @Saudi_fda_en Get rdy this week Remember before end of this coming week you will see something unexpected 🤣🤣 $IBRX #ImmunityBio #BiotechInvesting #CancerTreatment #GlobalMarkets"
X Link 2026-02-14T16:32Z [---] followers, [----] engagements
"$IBRX is not just a biotech stock This is a battle between long-term investors and short sellers. Fridays move was pressure not weakness. The $6 support is still intact and the $5.80 $7.20 range remains. Market law is simple: The more pressure on a fundamentally improving company the closer the breakout. 🔹 Revenue growth 🔹 Global expansion 🔹 Strategic partnerships 🔹 Strong institutional attention 🔹 Elevated short interest Next week could be the turning point. If $7.20 breaks with strong volume Shorts will have no place to hide. From Riyadh we see the big picture not the short-term noise."
X Link 2026-02-14T01:11Z [---] followers, [----] engagements
"$IBRX is not trading like a normal stock right now. This is a high-pressure setup in the biotech sector. The last-hour weakness on Friday does not signal structural breakdown. It reflects a well-known pattern in heavily shorted catalyst-driven stocks. 📊 Technically: The stock remains in a clear consolidation range between $5.80 $7.20 with strong psychological and technical support at $6. The volume spike into the close suggests: ✔ Reactive selling not institutional distribution ✔ Continued short pressure ✔ Quiet accumulation ahead of potential catalysts 📉 Market law is simple: The stronger"
X Link 2026-02-14T00:03Z [---] followers, [----] engagements
"Remember when i said we will reach 15$ this feb and beginning of march [----] $IBRX"
X Link 2026-02-13T15:46Z [---] followers, [----] engagements
"China expanding PD-1 combinations at scale. Japan advancing next-gen CAR-T & proton therapy. Russia announcing oncology vaccines. Innovation moves fast. Paperwork moves thoughtfully. 🗂 From Riyadh to Wall Street capital follows momentum not hesitation. 📈 Lets see who approves first and who just keeps refreshing the page. 👀 $IBRX #Biotech #Oncology #Innovation #GlobalMarkets #WallStreet #FDA https://twitter.com/i/web/status/2021437209224655193 https://twitter.com/i/web/status/2021437209224655193"
X Link 2026-02-11T04:12Z [---] followers, [----] engagements
"My call: $IBRX above $15 before the end of February. This is a conviction not noise. If it doesnt happen Ill run a cash giveaway by draw for followers then Ill close this account. Remember this clearly: The real game isnt on Wall Street. The game is in Riyadh Saudi arbia Some will remember this post. Others will regret ignoring it. If youre tracking this story repost and save it. $IBRX #ImmunityBio #Anktiva #BiotechStocks #Immunotherapy #Oncology #NKCells #SaudiHealthcare #NASDAQ https://twitter.com/i/web/status/2021349522346012974 https://twitter.com/i/web/status/2021349522346012974"
X Link 2026-02-10T22:24Z [---] followers, 10.5K engagements
"It will be interesting to see how short positions react over the next few days. The market has already been given plenty of signals now price action and volume will do the talking. 🚀"
X Link 2026-02-11T03:49Z [---] followers, [---] engagements
"RT @truedat999: $IBRX GAMMA + SHORT SQUEEZE LOADED Hold $7.50 & Watch Shorts Panic to $11$12🔥 @IdenixixH Spot on Real-time short intere"
X Link 2026-02-11T03:44Z [---] followers, [--] engagements
"$IBRX GAMMA + SHORT SQUEEZE LOADED Hold $7.50 & Watch Shorts Panic to $11$12🔥 @IdenixixH Spot on Real-time short interest 135M (40%+ float) per Fintel/NASDAQ borrow rates high (8.89%) days to cover [---] (shorts need a full week+ to escape if volume stays hot). Official next report: Settlement Jan [--] (out Feb 3) then Feb [--] (out Feb 18) daily data building the pressure Gamma squeeze fuel loading tons of call options bets at $7.5 & $10 mean big firms might have to buy shares to hedge creating extra upward rocket power if we break higher Closed $6.93 yesterday (+14.5%) holding $7 today. Buy &"
X Link 2026-02-10T20:39Z [----] followers, [----] engagements
"$IBRX Short interest now at [---------] shares. This is 40% of the float. This is very exciting news to me"
X Link 2026-02-10T19:16Z [---] followers, [----] engagements
"Clinical benefit is no longer a theoretical discussion it is being applied. $IBRXs lead asset Anktiva (N-803) is supported by late-stage peer-reviewed clinical data including: 70% complete response rates in BCG-unresponsive NMIBC Durable responses measured in years not months Consistent immune activation through NK cells and CD8+ T cells This efficacy has already justified real-world clinical use not just trial continuation. Importantly Saudi Arabia has already begun integrating advanced immunotherapies into clinical practice aligned with its national oncology strategy and healthcare"
X Link 2026-02-10T22:09Z [---] followers, [---] engagements
"What we saw today in $IBRX looks like a final aggressive short attempt into the close. Heavy selling pressure. Maximum fear tactics. Stops flushed. Yet the fundamentals didnt change. The science didnt change. And the setup didnt break. When downside pressure is exhausted and volume returns the unwind can be fast. Do your own research. Understand the risk. But dont confuse volatility with weakness. Sometimes the loudest move comes after the quietest close. We should buy 50-100 stock today Share this tweet $IBRX #ImmunityBio #Anktiva #Biotech #BiotechStocks #Immunotherapy #CancerResearch"
X Link 2026-02-10T21:12Z [---] followers, [----] engagements
"What happened today in $IBRX was purely technical not bad news not a change in fundamentals. Price hit a major resistance zone (7.1x) Smart money distributed into strength Stops were hunted And algos did their job into the close. RSI reached oversold levels Volume confirms distribution not panic Key support held around the mid-6s This looks like cleanup before the next move not the end of the story. The science hasnt changed. Anktivas trajectory is intact. And in biotech silence often comes right before catalysts. $IBRX #ImmunityBio #Anktiva #Biotech #BiotechStocks #CancerResearch"
X Link 2026-02-10T21:09Z [---] followers, [----] engagements
"if you did this about trading"
X Link 2026-02-08T21:15Z 175.8K followers, 121.1K engagements
"Eyes on the clock Next [---] minutes should tell the story what do you think $IBRX #ImmunityBio #BiotechInvesting #CancerTreatment #Biotech #Stocks #StockMarket #WallStreet #Trading #DayTrading #GlobalMarkets"
X Link 2026-02-10T15:12Z [---] followers, [----] engagements
"I am seeing [----] tonight 🤓 even if we are at [----] $IBRX #ImmunityBio #BiotechInvesting #CancerTreatment #GlobalMarkets"
X Link 2026-02-10T14:53Z [---] followers, [----] engagements
Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing